LONDON — The race for a vaccine against the coronavirus intensified on Monday as three competing laboratories released promising results from early trials in humans.
Now comes the hard part: proving that any of the vaccines protects against the virus, and establishing how much immunity they provide — and for how long.
“What this means is that each of these vaccines is worth taking all the way through to a Phase III study,” said Dr. Peter Jay Hotez, a vaccine researcher at the Baylor College of Medicine. “That is it. All it means is ‘worth pursuing.’” Phase III trials test how well a drug works.
Two of the vaccine developers — the first, a partnership between Oxford University and the British-Swedish drug maker AstraZeneca; the second, the Chinese company CanSino Biologics — published their early results as peer-reviewed studies in The Lancet, a British medical journal.
A joint venture between the drug giant Pfizer and the German company BioNTech shared results online before peer review, and invited comparisons to the biotech company Moderna, which uses a similar technology and released early results last week.
All the developers that released results on Monday said their vaccines had produced strong immune responses with only minor side effects.
“They all look really good,” said Prof. Stacey Schultz-Cherry of the St. Jude Children’s Research Hospital, arguing that more than one vaccine would be necessary to address the needs of varying demographic groups.
All of the developers asserted that their vaccines elicited antibody levels similar to those seen in patients who have recovered from Covid-19.
But scientists cautioned that the antibody responses in convalescing patients varied widely, and that even matching those responses did not necessarily guarantee any degree of immunity.
“It does not really tell you whether the vaccine is going to protect,” said Prof. John P. Moore of Weill Cornell Medical College.
The developers who announced their early results Monday all indicated that any immunity was likely to require a second, booster dose of its vaccine.
The partnership between Oxford and AstraZeneca may be the most closely watched vaccine effort.
The United States, Britain and several other governments and nonprofit groups have already agreed to pay hundreds of millions of dollars for a total of two billion doses even before the vaccine’s efficacy has been proven. And British and American officials believe Russia sought to spy on the Oxford research.
It was also the first vaccine to enter Phase III trials.
More than 10,000 participants in Britain, Brazil and South Africa have already received doses. Another Phase III test involving 30,000 participants in the United States is set to begin next week, along with a parallel test of the Moderna vaccine.
The Oxford study released on Monday analyzed a few hundred participants who had received the vaccine in an earlier safety trial. Of those, only 10 received a booster shot, and they showed the most promising immune response.
“There is still a long way to go,” said Prof. Sarah Gilbert of Oxford, who is leading development of the vaccine.
The CanSino vaccine, tested in a trial of about 500 participants in China, appeared least likely to be effective, based on the early results released so far, scientists said. “Pretty weak compared to other vaccine candidates (to the extent that comparisons are possible),” Professor Moore noted in a summary of the results.
Both the Oxford and CanSino vaccines work by altering the genes of another common virus — the adenovirus — so that it harmlessly mimics the coronavirus and induces an immune response.
The Oxford vaccine exploits an adenovirus found in chimps; humans do not already have antibodies against it. The CanSino vaccine, on the other hand, travels on the back of a widespread adenovirus that causes the common cold in humans, and so pre-existing defenses against that adenovirus in many people appear to thwart the vaccine, scientists said.
The preliminary results released Monday by the Pfizer-BioNTech partnership, based on a trial with 60 participants in Germany at various dosage levels, appeared able to produce a strong immune response. The vaccine uses the same kind of specially engineered genetic material, mRNA, as the Moderna vaccine, and the early results from Pfizer-BioNTech may suggest an even stronger immune response, scientists said.
But the scientists cautioned that no response in a lab test guarantees that a vaccine will prevent a disease. And comparing the immune responses ascribed to the various vaccines is almost impossible because the reports are not standardized.
“It’s like judging a beautiful baby photo contest when every mom uses a different Instagram filter,” Professor Moore said.
What’s more, none of the trials has been able to measure results over more than a few weeks, raising questions about the longer term effects of the vaccines.
Professor Hotez argued that the eagerness of vaccine developers to promote such inconclusive results may actually undermine more immediate public health efforts to control the virus, like wearing masks and social distancing.
“All the hype makes it seem like a miracle is around the corner,” he said, “and that is just not the case. This is not going to be a quick fix. This is going to take years to sort out.”
Carl Zimmer contributed reporting.
JACKSONVILLE, Fla. – Public health officials are expressing alarm after early data is showing that an overwhelming number of African American residents are among those dying of COVID-19.
Black residents accounted for 72% of deaths from complications of coronavirus disease in Chicago and 52% of positive tests for the coronavirus, despite blacks making up only 30% of the city’s population, according to the city’s public health agency.
Similar conditions mark other large cities with large black populations that are considered hot spots for the coronavirus, including New York, Detroit, Milwaukee and New Orleans. Figures released Monday by Michigan’s Department of Health and Human Services showed African Americans, who make up 14% of the state population, make up about 33% of cases statewide and 41% of deaths.
A new team of city and community representatives will focus on contacting residents who are older than 50 and those considered vulnerable to the virus because of other health conditions to share information about prevention and resources for those who do become ill.
A national civil rights group on Monday said that’s a problem across the country and demanded more transparency on race and ethnicity among the COVID-19 testing results, cases and patient outcomes reported by federal health authorities and state health agencies.
“Equal access to healthcare is a critical civil rights issue, and during this novel pandemic, the public deserves nothing less than full transparency from this administration and state public health officials,” Kristen Clarke, president and executive director of Lawyers’ Committee for Civil Rights Under Law, said in a statement.
One of the nation’s top experts on the pandemic, Dr. Anthony Fauci, said coronavirus is “shining a bright light” on unacceptable health disparities for African-Americans.
There’s a push for data showing the race of COVID-19 patients in Florida and a state senator is pushing for more testing in black neighborhoods.
“I asked directly to the surgeon general, then we had a conference call with the surgeon general last week asking for that information,” Gibson said.
Data released by the Florida Department of Health over the weekend shows 21% of people hospitalized with the COVID-19 in Florida are black. According to 2018 U.S. Census figures, 16% of Florida residents are listed as black or African-American.
UF Health Jacksonville began an outreach Wednesday to people who live in a public housing project in Jacksonville’s Durkeeville neighborhood lined up to be tested for COVID-19. Free testing is available to people, especially those at least 65 years of age.
“I am not that familiar with the internet,” said 83-year-old resident Suzy Henry. “So I am grateful and happy they are here today making it convenient for people like me.”
African-American and Hispanic populations typically have are higher rates of hypertension, diabetes and high-cholesterol and income disparity can result in a lower level of preventative health care.
“We haven’t quite seen what we’ve seen in Chicago, Milwaukee, in terms of a racial perspective, but that’s why we are out here, So we can learn more and hopefully put in some interventions,” Dr. Leon Haley of UF Health.
Florida Gov. Ron Desantis also addressed the issue at a news briefing Wednesday.
“We’re now breaking out by race or ethnicity. (We) don’t have it for every patient, but the ones we do we’re putting it there,” DeSantis said. “We’re also with the University of Florida and Shands … a kind of an investigation into some of the public housing communities … where they maybe not getting what they need.”
Copyright 2020 by WJXT News4Jax – All rights reserved.